拉帕替尼对 HER2 阴性乳腺癌有效吗？
Does lapatinib work against HER2-negative breast cancers?
机构信息
Departments of Medicine, Vanderbilt-Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA.
出版信息
Clin Cancer Res. 2010 Mar 1;16(5):1355-7. doi: 10.1158/1078-0432.CCR-09-3223. Epub 2010 Feb 23.
Abstract
Aberrant growth factor receptor signaling can augment or suppress estrogen receptor (ER) function in hormone-dependent breast cancer cells and lead to escape from anti-estrogen therapy. Interruption of HER2/ER cross-talk with lapatinib can restore sensitivity to anti-estrogens and thus, should be investigated in combination with endocrine therapy in patients with ER+/HER2-negative breast cancers.
摘要
异常的生长因子受体信号可以增强或抑制激素依赖性乳腺癌细胞中的雌激素受体 (ER) 功能，并导致逃避抗雌激素治疗。用拉帕替尼阻断 HER2/ER 交叉对话可以恢复对抗雌激素药物的敏感性，因此，应在 ER+/HER2-阴性乳腺癌患者中与内分泌治疗联合进行研究。
相似文献
1
Does lapatinib work against HER2-negative breast cancers?拉帕替尼对 HER2 阴性乳腺癌有效吗？
Clin Cancer Res. 2010 Mar 1;16(5):1355-7. doi: 10.1158/1078-0432.CCR-09-3223. Epub 2010 Feb 23.
2
Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.拉帕替尼恢复激素敏感性，并对获得内分泌耐药的人表皮生长因子受体 2 阴性乳腺癌细胞模型中的雌激素受体信号产生差异影响。
Clin Cancer Res. 2010 Mar 1;16(5):1486-97. doi: 10.1158/1078-0432.CCR-09-1764. Epub 2010 Feb 23.
3
Mechanisms of lapatinib resistance in HER2-driven breast cancer.曲妥珠单抗耐药机制在 HER2 驱动型乳腺癌中的作用。
Cancer Treat Rev. 2015 Dec;41(10):877-83. doi: 10.1016/j.ctrv.2015.08.001. Epub 2015 Aug 8.
4
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy.雌激素受体（ER）信号上调作为抗HER2治疗的HER2阳性乳腺肿瘤细胞存活的一种适应性机制
Clin Cancer Res. 2015 Sep 1;21(17):3995-4003. doi: 10.1158/1078-0432.CCR-14-2728. Epub 2015 May 26.
5
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.他莫昔芬耐药机制：雌激素受体与HER2/neu在ER/HER2阳性乳腺癌中相互作用增强
J Natl Cancer Inst. 2004 Jun 16;96(12):926-35. doi: 10.1093/jnci/djh166.
6
Overcoming treatment resistance in HER2-positive breast cancer: potential strategies.克服 HER2 阳性乳腺癌的治疗耐药性：潜在策略。
Drugs. 2012 Jun 18;72(9):1175-93. doi: 10.2165/11634000-000000000-00000.
7
De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.曲妥珠单抗治疗 HER2 阳性乳腺癌的降级治疗：反应的决定因素和耐药机制。
Breast. 2017 Aug;34 Suppl 1(Suppl 1):S19-S26. doi: 10.1016/j.breast.2017.06.022. Epub 2017 Jul 4.
8
Progression and treatment of HER2-positive breast cancer.HER2 阳性乳腺癌的进展和治疗。
Cancer Chemother Pharmacol. 2010 Mar;65(4):611-23. doi: 10.1007/s00280-009-1208-1. Epub 2009 Dec 20.
9
A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer.一种对强效表皮生长因子受体2（ErbB2）酪氨酸激酶抑制剂获得性自身耐药的模型以及预防其在乳腺癌中发生的治疗策略。
Proc Natl Acad Sci U S A. 2006 May 16;103(20):7795-800. doi: 10.1073/pnas.0602468103. Epub 2006 May 8.
10
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.来曲唑联合拉帕替尼对比来曲唑联合安慰剂作为绝经后激素受体阳性转移性乳腺癌的一线治疗。
J Clin Oncol. 2009 Nov 20;27(33):5538-46. doi: 10.1200/JCO.2009.23.3734. Epub 2009 Sep 28.
引用本文的文献
1
Identification of potential new treatment response markers and therapeutic targets using a Gaussian process-based method in lapatinib insensitive breast cancer models.在拉帕替尼不敏感的乳腺癌模型中，使用基于高斯过程的方法鉴定潜在的新治疗反应标志物和治疗靶点。
PLoS One. 2017 May 8;12(5):e0177058. doi: 10.1371/journal.pone.0177058. eCollection 2017.
2
Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells.一种可测量活乳腺癌细胞系和原代细胞中实时HER2信号传导功能的检测方法的开发。
BMC Cancer. 2017 Mar 16;17(1):199. doi: 10.1186/s12885-017-3181-0.
3
Trichostatin A suppresses EGFR expression through induction of microRNA-7 in an HDAC-independent manner in lapatinib-treated cells.曲古抑菌素A在拉帕替尼处理的细胞中以不依赖组蛋白去乙酰化酶的方式通过诱导微小RNA-7来抑制表皮生长因子受体的表达。
Biomed Res Int. 2014;2014:168949. doi: 10.1155/2014/168949. Epub 2014 Feb 23.
4
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.双靶点表皮生长因子受体/人表皮生长因子受体2抑制剂AZD8931克服内分泌耐药的治疗潜力
Breast Cancer Res Treat. 2014 Apr;144(2):263-72. doi: 10.1007/s10549-014-2878-x. Epub 2014 Feb 20.
5
BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib.BCAR4 导致抗雌激素耐药，但使乳腺癌对拉帕替尼敏感。
Br J Cancer. 2012 Sep 4;107(6):947-55. doi: 10.1038/bjc.2012.351. Epub 2012 Aug 14.
6
Treatment of HER2-positive breast cancer: current status and future perspectives.人表皮生长因子受体 2 阳性乳腺癌的治疗：现状与未来展望。
Nat Rev Clin Oncol. 2011 Nov 29;9(1):16-32. doi: 10.1038/nrclinonc.2011.177.
本文引用的文献
1
Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.拉帕替尼恢复激素敏感性，并对获得内分泌耐药的人表皮生长因子受体 2 阴性乳腺癌细胞模型中的雌激素受体信号产生差异影响。
Clin Cancer Res. 2010 Mar 1;16(5):1486-97. doi: 10.1158/1078-0432.CCR-09-1764. Epub 2010 Feb 23.
2
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.曲妥珠单抗联合阿那曲唑对比阿那曲唑单药治疗人表皮生长因子受体 2 阳性、激素受体阳性转移性乳腺癌绝经后女性患者：来自随机 III 期 TAnDEM 研究的结果。
J Clin Oncol. 2009 Nov 20;27(33):5529-37. doi: 10.1200/JCO.2008.20.6847. Epub 2009 Sep 28.
3
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.来曲唑联合拉帕替尼对比来曲唑联合安慰剂作为绝经后激素受体阳性转移性乳腺癌的一线治疗。
J Clin Oncol. 2009 Nov 20;27(33):5538-46. doi: 10.1200/JCO.2009.23.3734. Epub 2009 Sep 28.
4
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.在阿那曲唑、他莫昔芬单独或联合使用试验中，定量雌激素和孕激素受体表达与人类表皮生长因子受体2（HER-2）状态与复发之间的关系。
J Clin Oncol. 2008 Mar 1;26(7):1059-65. doi: 10.1200/JCO.2007.12.9437. Epub 2008 Jan 28.
5
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.雌激素受体与HER酪氨酸激酶受体家族之间的相互作用：分子机制及对内分泌治疗耐药性的临床意义
Endocr Rev. 2008 Apr;29(2):217-33. doi: 10.1210/er.2006-0045. Epub 2008 Jan 23.
6
Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.人表皮生长因子受体2状态与雌激素受体（ER）阴性患者的淋巴结受累相关，但与适合细胞毒性化疗的ER阳性早期乳腺癌患者的分级相关。
J Clin Oncol. 2007 Oct 1;25(28):4423-30. doi: 10.1200/JCO.2007.11.0973.
7
A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer.一种对强效表皮生长因子受体2（ErbB2）酪氨酸激酶抑制剂获得性自身耐药的模型以及预防其在乳腺癌中发生的治疗策略。
Proc Natl Acad Sci U S A. 2006 May 16;103(20):7795-800. doi: 10.1073/pnas.0602468103. Epub 2006 May 8.
8
Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.体外雌激素受体α阳性乳腺癌细胞中丝裂原活化蛋白激酶的激活可诱导雌激素受体α阴性人类乳腺肿瘤的体内分子表型。
Cancer Res. 2006 Apr 1;66(7):3903-11. doi: 10.1158/0008-5472.CAN-05-4363.
9
Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy.在接受曲妥珠单抗联合化疗的HER-2过表达晚期乳腺癌患者中逆转雌激素受体阴性表型。
Breast Cancer Res. 2006;8(1):R4. doi: 10.1186/bcr1366. Epub 2005 Dec 7.
10
The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.新型双靶点ErbB-2/EGFR酪氨酸激酶抑制剂的特性：癌症的潜在治疗方法
Cancer Res. 2001 Oct 1;61(19):7196-203.
Zotero 插件